Vericel Corp. (VCEL)
58.52
+0.26
(+0.45%)
USD |
NASDAQ |
Nov 20, 11:01
Vericel Cash from Investing (Quarterly) : -2.708M for Sept. 30, 2026
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | -2.708M |
| June 30, 2026 | -2.82M |
| March 31, 2026 | -4.201M |
| December 31, 2025 | -16.39M |
| September 30, 2025 | -3.377M |
| June 30, 2025 | -9.028M |
| March 31, 2025 | -15.14M |
| December 31, 2024 | -14.65M |
| September 30, 2024 | -21.21M |
| June 30, 2024 | -17.72M |
| March 31, 2024 | -25.45M |
| December 31, 2023 | -8.088M |
| September 30, 2023 | 4.566M |
| June 30, 2023 | -2.408M |
| March 31, 2023 | 2.80M |
| December 31, 2022 | -21.73M |
| September 30, 2022 | -0.811M |
| June 30, 2022 | -2.997M |
| March 31, 2022 | -10.67M |
| December 31, 2021 | 1.885M |
| September 30, 2021 | -2.629M |
| June 30, 2021 | -14.94M |
| March 31, 2021 | 12.19M |
| December 31, 2020 | -25.68M |
| September 30, 2020 | -17.44M |
| Date | Value |
|---|---|
| June 30, 2020 | 12.21M |
| March 31, 2020 | 13.74M |
| December 31, 2019 | -14.60M |
| September 30, 2019 | 13.37M |
| June 30, 2019 | -3.811M |
| March 31, 2019 | 15.66M |
| December 31, 2018 | -20.45M |
| September 30, 2018 | -45.60M |
| June 30, 2018 | -0.795M |
| March 31, 2018 | -0.184M |
| December 31, 2017 | -0.718M |
| September 30, 2017 | -0.519M |
| June 30, 2017 | -0.203M |
| March 31, 2017 | -0.07M |
| December 31, 2016 | -0.101M |
| September 30, 2016 | -0.333M |
| June 30, 2016 | -1.061M |
| March 31, 2016 | 0.08M |
| December 31, 2015 | -0.097M |
| September 30, 2015 | -0.775M |
| June 30, 2015 | -1.202M |
| March 31, 2015 | -0.318M |
| December 31, 2014 | -0.646M |
| September 30, 2014 | -2.568M |
| June 30, 2014 | 1.036M |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | -86.15M |
| Alnylam Pharmaceuticals, Inc. | -311.74M |
| Anika Therapeutics, Inc. | -1.756M |
| Savara, Inc. | 31.01M |
| Arrowhead Pharmaceuticals, Inc. | 203.86M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 17.72M |
| Cash from Financing (Quarterly) | -6.88M |
| Free Cash Flow | 57.89M |
| Free Cash Flow Per Share (Quarterly) | 0.2961 |
| Free Cash Flow to Equity (Quarterly) | 17.66M |
| Free Cash Flow to Firm (Quarterly) | 15.84M |
| Free Cash Flow Yield | 1.94% |